John Martin Argentina

Ranitidina 20 Inyectable

Anti-ulcer agent

Ranitidine is an H2 receptor antagonist with anti-ulcer action that reduces gastric acid secretion. Its effect is produced by blocking H2 receptors in the parietal cells, which reduces acidity and helps protect the gastric mucosa.

Ranitidina20 inyectable
TARGET SPECIES
Dogs and cats.
DOSAGE FORM
Injectable suspension.
HOW SUPPLIED
50 mL vial.
DIFFERENTIATORS

BENEFITS AND COMPETITIVE ADVANTAGES

Allows control of acid secretion in acute situations.
Can be used to start parenteral therapy and then continue orally, facilitating the therapeutic transition.

Can be used to start parenteral therapy and then continue orally, facilitating the therapeutic transition.

Allows control of acid secretion in acute situations.

Can be used to start parenteral therapy and then continue orally, facilitating the therapeutic transition.

TECHNICAL DETAILS

Information

– Ranitidine hydrochloride 20 mg.
– Excipients q.s. to 1 ml.
Administer subcutaneously (SC), intramuscularly (IM), or by slow intravenous (IV) injection after prior dilution.
Dogs: 2 mg/kg, equivalent to 1 mL per 10 kg. Repeat every 12 hours.
Cats: 2.5 mg/kg, equivalent to 1 mL per 8 kg. Repeat every 12 hours.
Dosage and treatment duration may be adjusted based on the clinical picture, at the discretion of the attending veterinary professional.

Ranitidina 20 Inyectable

TARGET SPECIES
Dogs and cats.
DOSAGE FORM
Injectable suspension.
HOW SUPPLIED
50 mL vial.
Anti-ulcer agent

Ranitidine is an H2 receptor antagonist with anti-ulcer action that reduces gastric acid secretion. Its effect is produced by blocking H2 receptors in the parietal cells, which reduces acidity and helps protect the gastric mucosa.

Allows control of acid secretion in acute situations.
Can be used to start parenteral therapy and then continue orally, facilitating the therapeutic transition.

Can be used to start parenteral therapy and then continue orally, facilitating the therapeutic transition.

Allows control of acid secretion in acute situations.

Can be used to start parenteral therapy and then continue orally, facilitating the therapeutic transition.

TECHNICAL DETAILS

Information

– Ranitidine hydrochloride 20 mg.
– Excipients q.s. to 1 ml.
Administer subcutaneously (SC), intramuscularly (IM), or by slow intravenous (IV) injection after prior dilution.
Dogs: 2 mg/kg, equivalent to 1 mL per 10 kg. Repeat every 12 hours.
Cats: 2.5 mg/kg, equivalent to 1 mL per 8 kg. Repeat every 12 hours.
Dosage and treatment duration may be adjusted based on the clinical picture, at the discretion of the attending veterinary professional.
Scroll to Top